Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: ATROVENT® inhalets

Study type: Observational

Funder types: Industry

Identifiers

NCT02238132

244.2491

Details and patient eligibility

About

To obtain further information on the tolerability of Atrovent® inhalets in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

Enrollment: 374 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primarily, Patients with chronic obstructive airways disease
• Only patients who had not been treated with Atrovent® in the last year were to be considered for inclusion

Exclusion criteria

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® inhalets

Trial design

374 participants in 1 patient group

Chronic Obstructive Airways Disease

Treatment:

Drug: ATROVENT® inhalets